TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07502300: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 for Injection Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Ext

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 562 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07502300 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07502300 Rescue Dossier →